{"id":1365,"date":"2000-08-01T12:05:00","date_gmt":"2000-08-01T10:05:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2000\/ueberempfindlichkeit-gegen-ciprofloxacin-und-gegen-das-neue-5-asa-prodrug-balsalazid"},"modified":"2000-08-01T12:05:00","modified_gmt":"2000-08-01T10:05:00","slug":"ueberempfindlichkeit-gegen-ciprofloxacin-und-gegen-das-neue-5-asa-prodrug-balsalazid","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2000\/ueberempfindlichkeit-gegen-ciprofloxacin-und-gegen-das-neue-5-asa-prodrug-balsalazid","title":{"rendered":"\u00dcberempfindlichkeit gegen Ciprofloxacin und gegen das neue 5-ASA-Prodrug Balsalazid"},"content":{"rendered":"<p>In British Medical Journal erscheinen in unregelm\u00e4\u00dfigen Abst\u00e4nden Mitteilungen zu unerw\u00fcnschten Arzneimittelwirkungen unter dem Titel &#8222;Drug points&#8220;. Im Brit. Med. J. X2000, 342, 1824 berichten P. Burke und S.R. Burne aus Oxford \u00fcber Meningokokken-Meningitiden an der Universit\u00e4t Oxford. Zwei Studenten erkrankten innerhalb von 12 Tagen; einer starb. Um erneute Krankheitsf\u00e4lle zu verh\u00fcten, ist es \u00fcblich, [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In British Medical Journal erscheinen in unregelm\u00e4\u00dfigen Abst\u00e4nden Mitteilungen zu unerw\u00fcnschten Arzneimittelwirkungen unter dem Titel &#8222;Drug points&#8220;. Im Brit. Med. J. X2000, 342, 1824 berichten P. Burke und S.R. Burne aus Oxford \u00fcber Meningokokken-Meningitiden an der Universit\u00e4t Oxford. Zwei Studenten erkrankten innerhalb von 12 Tagen; einer starb. Um erneute Krankheitsf\u00e4lle zu verh\u00fcten, ist es \u00fcblich, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[3296,294],"class_list":["post-1365","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-balsalazid","tag-ciprofloxacin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1365","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1365"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1365\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1365"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1365"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1365"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}